Cognitive impairment and decline in cognitively normal older adults with high amyloid-b: A meta-analysis
June 1, 2017
The scientific community widely agrees that in cognitively normal older adults, abnormal levels of amyloid-beta, seen through PET imaging or CSF sampling, indicates that the pathophysiological process of Alzheimer’s disease has, in fact, begun; although it may still be decades before these individuals meet clinical criteria for dementia. Despite being cognitively normal, studies show that […]
Measuring Cognition in Oncology Trials
December 22, 2015
The third entry in Cogstate’s podcast series on measuring cognition in clinical trials focuses on cognitive measures specifically in oncology trials. Dr. Brian Harel, Clinical Science Director at Cogstate and Assistant Clinical Professor at the Yale University School of Medicine, Child Study Center, discusses the methodologies used to measure cognition in oncology trials, as well […]
Cognitive Measures in Pediatric Drug Development: Key Considerations, Tools and Technologies
November 16, 2015
The second podcast in our series – ‘Cognitive Measures in Pediatric Drug Development: Key Considerations, Tools and Technologies’ – sees Dr. Brian Harel, Clinical Science Director at Cogstate discussing the requirements of pharmaceutical companies by regulators to collect data on the effects of their treatments on children, and the challenge to find ways to minimize […]
Early Phase Decision Making About Cognitive Safety
September 22, 2015
The first entry in Cogstate’s podcast series – ‘Measuring Cognition in Clinical Trials’ – sees Professor Paul Maruff, Chief Scientific Officer at Cogstate, discussing methodology for measuring cognition in early phase research, as well as delving into the details of computerized cognitive tests and their impact on drug development decision making. Professor Maruff also explains […]
